VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...

If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

Troy Pruett, a Grapevine resident, will be competing in his 96th marathon this weekend and getting one step closer to the ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

It was seven months later when she was diagnosed with amyotrophic lateral sclerosis and bulbar palsy, both neurological ...

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...